文献速递流行病学与生物统计临床试验与 GCP

酒精使用障碍与抑郁障碍共病成人临床干预的系统综述与网络Meta分析

Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis.
PubMed 文献 · PLoS Med · 2021-10-08

该系统综述与网络Meta分析纳入36项RCT共2729名酒精使用障碍与抑郁障碍共病成人,评估14种药物和4种心理干预辅助常规治疗的效果。对抑郁缓解和酒精使用缓解的主要结局证据确定性极低;CBT可能改善抑郁症状,SSRIs可能改善功能状态但增加不良事件风险。

要点

  • 共病成人主要结局(抑郁缓解、酒精使用缓解)的证据确定性极低。
  • CBT对抑郁症状的改善有中等确定性证据支持。
  • SSRIs可能改善功能状态,但不良事件风险可能增加。

核心结论

  • 对抑郁缓解和酒精使用缓解是否存在非零效应非常不确定。
  • 现有证据提示CBT可能减轻抑郁症状,TCAs可能轻微减轻抑郁症状。
  • SSRIs可能改善功能状态,SSRIs和CBT可能轻微减少酒精使用,但SSRIs可能增加不良事件风险。

研究设计与样本

  • 纳入36项RCT共2729名共病成人,评估14种药物和4种心理干预辅助常规治疗。
  • 研究发表于1971至2019年,来自13个国家,中位样本量50人(范围14至350人)。

主要发现

  • CBT对抑郁症状优于无额外治疗(SMD=-0.84;95%CI -1.05至-0.63;p<0.001),中等确定性。
  • CBT对酒精使用(SMD=-0.25;95%CI -0.47至-0.04;p=0.021),低确定性。
  • TCAs对抑郁症状优于安慰剂(SMD=-0.37;95%CI -0.72至-0.02;p=0.038),低确定性。
  • SSRIs对功能状态优于安慰剂(SMD=-0.92;95%CI -1.36至-0.47;p<0.001),中等确定性。
  • SSRIs对酒精使用(SMD=-0.30;95%CI -0.59至-0.02;p=0.039),低确定性;不良事件(OR=2.20;95%CI 0.94至5.16;p=0.07),中等确定性。

关键数值与推荐

  • 主要结局为抑郁缓解和酒精使用缓解,所有效应估计证据确定性极低。
  • 连续结局使用标准化均数差(SMD),二分类结局使用比值比(OR)。
  • 采用GRADE方法评估证据确定性,未有任何结局达到高确定性。

临床怎么用

  • CBT可考虑用于改善共病成人的抑郁症状。
  • SSRIs可能改善功能状态但需关注不良事件风险。
  • TCAs可能轻微改善抑郁症状,但证据确定性低。

局限性

  • 长期干预效果的证据稀少。
  • 存在失访偏倚风险。
  • 不良事件定义异质性大。
  • 结论仅适用于干预后,且未与活性对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uncertainty remains regarding the effectiveness of treatments for patients diagnosed with both an alcohol use disorder (AUD) and depressive disorder. This study aimed to compare the effectiveness of clinical interventions for improving symptoms of adults with co-occurring AUDs and depressive disorders. METHODS AND FINDINGS: We searched CINAHL, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Excerpta Medica Database, International Clinical Trials Registry Platform (ICTRP), PubMed, PsycINFO, and Web of Science from inception to December 2020. We included randomized controlled trials (RCTs) evaluating clinical interventions for adults with co-occurring AUDs and depressive disorders. Two independent reviewers extracted study-level information and outcome data. We assessed risk of bias using the Cochrane Risk of Bias tool, used frequentist random effects models for network meta-analyses, and rated our confidence in effect estimates using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Primary outcomes were remission from depression and alcohol use. Secondary outcomes were depressive symptoms, alcohol use, heavy drinking, health-related quality of life, functional status, and adverse events. We used standardized mean differences (SMDs) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes to estimate intervention effects. Overall, 36 RCTs with 2,729 participants evaluated 14 pharmacological and 4 psychological interventions adjunctive to treatment as usual (TAU). Studies were published from 1971 to 2019, conducted in 13 countries, and had a median sample size of 50 participants (range: 14 to 350 participants). We have very low confidence in all estimates of intervention effects on our primary outcomes (i.e., remission from depression and remission from alcohol use). We have moderate confidence that cognitive behavioral therapies (CBTs) demonstrated greater benefit than no additional treatment (SMD = -0.84; 95% confidence interval [CI], -1.05 to -0.63; p < 0.001) for depressive symptoms and low confidence (SMD = -0.25; 95% CI, -0.47 to -0.04; p = 0.021) for alcohol use. We have low confidence that tricyclic antidepressants (TCAs) demonstrated greater benefit than placebo (SMD = -0.37; 95% CI, -0.72 to -0.02, p = 0.038) for depressive symptoms. Compared with placebo, we have moderate confidence that selective serotonin reuptake inhibitors (SSRIs) demonstrated greater benefit for functional status (SMD = -0.92; 95% CI, -1.36 to -0.47, p < 0.001) and low confidence for alcohol use (SMD = -0.30; 95% CI, -0.59 to -0.02, p = 0.039). However, we have moderate confidence that patients receiving SSRIs also were more likely to experience an adverse event (OR = 2.20; 95% CI, 0.94 to 5.16, p = 0.07). We have very low confidence in all other effect estimates, and we did not have high confidence in any effect estimates. Limitations include the sparsity of evidence on intervention effects over the long term, risks of attrition bias, and heterogeneous definitions of adverse events in the evidence base. CONCLUSIONS: We are very uncertain about the existence (or not) of any non-null effects for our primary outcomes of remission from depression and remission from alcohol use. The available evidence does suggest that CBTs likely reduced, and TCAs may have resulted in a slight reduction of depressive symptoms. SSRIs likely increased functional status, and SSRIs and CBTs may have resulted in a slight reduction of alcohol use. However, patients receiving SSRIs also likely had an increased risk of experiencing an adverse event. In addition, these conclusions only apply to postintervention and are not against active comparators, limiting the understanding of the efficacy of interventions in the long term as well as the comparative effectiveness of active treatments. As we did not have high confidence in any outcomes, additional studies are warranted to provide more conclusive evidence.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Grant S, Azhar G, Han E, et al. Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis. PLoS Med. 2021. PMID: 34624018. doi:10.1371/journal.pmed.1003822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。